Basel, 9th July 2024 Matthias Schupp appointed as CEO of Medartis
|
Medartis Holding AG / Key word(s): Personnel PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Medartis today announced that its Board has appointed Matthias Schupp to the position of CEO, joining Medartis by the beginning of November. Matthias will succeed Christoph Brönnimann, who will ensure a seamless transition. Matthias brings excellent knowledge of the global medical technology sector, having held various senior leadership roles in Europe and Latin America at Straumann Group over the last 17 years. During his tenure at Straumann, he demonstrated a strong ability to perform and transform. In 2014, he assumed the post of SVP of LATAM at Straumann and in 2015 he also became CEO of Neodent, steering the LATAM region through ten years of significant growth and enabling Neodent to flourish into a leading global challenger brand. He was appointed to the Executive Management Board of Straumann in 2016. Matthias began his career in 1986 with Merck KGaA and rose through country management to the position of Regional Manager Latin America and USA. He moved to Wella in 2000 as Managing Director of the business in Russia and became Managing Director Professional Care Portugal in 2004, following the acquisition of Wella by P&G. Matthias attained a degree in Business Administration and International Business Studies in a dual system between Merck KGaA and the Darmstadt Business Academy. Marco Gadola, Chairman of Medartis, said: “Matthias is an exceptionally talented and dynamic leader with a track record of delivery, driving growth and developing winning teams. He brings with him deep expertise in medical technology as well as strong experience in both developed and developing markets. I’d like to thank Christoph Brönnimann for his years of great service and for continuing to lead Medartis until Matthias joins us later this year, and wish him all the best on his next journey.” Matthias added: “I am delighted to have been appointed as CEO of Medartis. It is a business with an impressive track record, a leading portfolio, a talented team and an excellent reputation. I am convinced by the strength of the business as well as its growth potential and look forward to leading Medartis into the next phase of development.”
About Medartis Contact: Medartis Holding AG Corporate Communications End of Inside Information |
| Language: | English |
| Company: | Medartis Holding AG |
| Hochbergerstrasse 60E | |
| 4057 Basel | |
| Switzerland | |
| Phone: | +41 61 633 34 34 |
| Fax: | +41 61 633 34 00 |
| E-mail: | info@medartis.com |
| Internet: | www.medartis.com |
| ISIN: | CH0386200239 |
| Valor: | 38620023 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1941861 |
| End of Announcement | EQS News Service |
|
|
1941861 09-Jul-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.